Mazen Zahlan

Watch Abhishek Singh and Durga SaiSri Ambati from Everest Group as they discuss the shifts in #LifeSciences as organizations move from traditional CRMs to #CustomerExperience Platforms (#CXP) and its profound impact on #healthcare and patient outcomes. Gain insights into the strategic implications of the #Salesforce-#Veeva split, the expanding role of #CRM in patient-centered care, and how future platforms will transform engagement across the healthcare ecosystem. Watch: https://okt.to/cq2oDM

4

Another great insights from ZS Atlas Intelligence on how consumers choices around weight management can have notable impacts on their behaviors in other categories as well. In their analysis, Russell Evans, Eric Swank and Harmandir Singh Bhasin observed that GLP-1 users are more likely to increase consumption of water and “named” diets like keto while reducing consumption of sugar, alcohol and carbs. Also, GLP-1s may inadvertently inhibit key behavior changes required for long-term success such as tracking nutritional intake or participating in exercise. Fascinating landscape to explore!

27

1 Comment

Life science’s CRM systems need to deliver personalized experiences, boost engagement and drive growth, but that’s unlikely without a radical rethink. ZS’s Mahmood Majeed and Srihari Sarangan share the vision for the next-gen CRM: https://bit.ly/3Te1jwN #Lifesciences #CRM #CommercialModel

2

ZS Impact Live - Boston. Started off with a bang with keynote from Pratap Khedkar What are the high priority areas pharma executives are investing in across Commercial, R&D, and Supply Chain? Despite all the excitement about AI and upside potential, the vast majority of life sciences companies’ AI investments have failed to scale. To build a capability that is all about scaling AI impact, there are 6 enablers : Mindset, Process, Data, Talent, Adoption, and Trust.

166

1 Comment

Diversity can be enhanced at every stage of the clinical trial process helping to advance healthcare equity. Check out RQM+'s latest white paper on diversity in clinical trials!

6

In their latest research, Gayatri B., Kara Ang Ke Qin and Zainul Jafferji laid out the status of #omnichannel scaling in #pharma across the geographies and capabilities. Some key learnings: (1) Omnichannel scaling has largely been limited to foundational capabilities and large, mature markets. (2) All pharma companies reported scaling at least one capability across M7 markets (the EU4, the U.K., Canada and Japan). (3) And 80% of respondents had scaled a data foundation, analytics and platform build to more than five markets It is also interesting to observe that there is no "one approach" to omnichannel that companies are taking across the board. for more - https://lnkd.in/dUBUThwz

23

4 Comments

Do you want to create impactful, standardized integrated evidence packages that deliver value? My ZS colleagues are helping life sciences move beyond disjointed efforts to transform evidence generation. Learn how you can reduce silos, standardize evidence generation, enhance planning and drive better strategies. #Pharma #IntegratedEvidence https://bit.ly/4fsi4h2

1

I’m happy to share a recent report from BCG on how patient analytics can play a crucial role in improving #healthequity. The report focuses on the significant disparities in treatment outcomes for Heart Failure with Reduced Ejection Fraction (HFrEF). The study reveals critical gaps, particularly in urban underserved areas, calling for urgent and strategic interventions. Read the report to learn about key actions #healthcare leaders can take to improve #healthequity: https://lnkd.in/euzj3tzW

17

What will it take to boost productivity in the biopharmaceutical industry, which has slumped for a decade or more? 📉 In this new article, my McKinsey colleagues Brandon Parry, Rachel Moss, Kate Smeitana, Michelle Suhendra spoke with hundreds of biopharma R&D leaders and drew on their own experience to help create a recipe for sustainable, value-creating innovation— even in the face of strengthening industry headwinds— to help make more medicines that matter to patients. Check it out here: https://lnkd.in/e_YutwMq #medicine #pharmaceuticals #research

18

BCG Roundtable Focused on Key Trends Shaping the Future of Clinical Operations   Was thrilled to host an energetic discussion at our inaugural Clinical Operations roundtable earlier this week with industry executives across biopharma to discuss the most pressing topics shaping these teams. Thank you to our BCG team that enabled this discussion John Wu, Najaf A. Shah Shah, Paul Hastwell, Deming Qin Rachel Magid Beatriz Monedero Álvarez. Four Key Trends from the Roundtable: 1. Simplifying Protocols to Improve Patient-Centricity and Equity Growing emphasis on reducing patient burden during clinical trials is reshaping clinical operations and clinical trial decision-making more broadly. Companies are leveraging data and analytics to design smarter, more inclusive trials while simplifying protocols for patients and sites. They are also bringing in patients to shape their protocols 2. Continuing to Accelerate Trial Timelines Site Activation and patient enrolment remain critical bottlenecks and a key discussion point, with participants sharing the strategies and initiatives they are pursuing (e.g., trial footprint and site mix adjustments, digital recruitment approaches and evolving site facing roles) to deliver trials faster. 3. Evolving Sourcing Models: To boost efficiency and capacity, companies are rethinking resource allocation, exploring more offshoring and functional service provider (FSP) to manage capacity; Full-service outsourcing (FSO) models still have a role, particularly for mid-sized companies and select studies 4. Harnessing (Gen)AI: GenAI is revolutionizing trial operations, from AI-powered design tools, automated document generation and dashboards to decentralized research and patient engagement. These innovations are set to enhance trial delivery and patient experience. Exciting times for Clinical Operations teams as they play a critical role in bringing medicines to patients faster in a cost-effective and efficient manner, with greater consideration of the patient experience and needs. To join us in future discussions, please get in touch at [email protected] #clinical, #trials, #GenAI

79

5 Comments

In this episode of Avira Digital's podcast, Sumati Rao, Ph.D, Senior Director of Oncology Value Evidence at GSK, explores the evolving role of medical affairs in pharma.  From shaping clinical decisions to driving data-driven strategies, Sumati highlights how value evidence engages stakeholders across the complex oncology ecosystem.  Join us in discovering how medical affairs is transforming into a strategic force in healthcare.  #RedefiningEvidenceManagement #MedicalAffairs #HEOR #OncologyInnovation #PharmaLeadership #HealthcareStrategy

45

2 Comments

My colleagues, Eric Berger, Robbie Sandig, and KC George shares how large and small pharma companies are succeeding with generative AI and the three-tiered approach guiding them to the forefront. Key takeaways include the importance of priming operating models and leveraging scale for breakthroughs.

3

1 Comment

From cancer and COVID vaccines to CAR-T therapies and GLP-1s, the pace of innovation in human health is unprecedented. But are we truly maximizing the potential of this “golden age for medicine” in terms of patient impact? Join ZS CEO Pratap Khedkar at #BioTechX Europe on Oct. 9 as he explores the critical challenges that hinder the translation of pharma innovations into real patient impact. Learn more: https://bit.ly/3zJoFE2

1

Amid tightening budgets, 50% of the top 20 leading pharma firms are prioritizing technology to achieve efficiency gains, as pressures on clinical services spending continue to grow. Uncover strategies for life sciences service providers to drive performance in a challenging market environment. https://atbain.co/41dK839

2

Patient engagement is no longer optional—it’s essential for life sciences companies. In this article, ZS experts explore how global patient engagement strategies are evolving and identify three critical dimensions of consideration for effective patient engagement: https://bit.ly/3WCudYi

3

Patient engagement is no longer optional—it’s essential for life sciences companies. In this article, ZS experts explore how global patient engagement strategies are evolving and identify three critical dimensions of consideration for effective patient engagement: https://bit.ly/3WCudYi

28

Patient engagement is no longer optional—it’s essential for life sciences companies. In this article, ZS experts explore how global patient engagement strategies are evolving and identify three critical dimensions of consideration for effective patient engagement: https://bit.ly/3WCudYi

2

Patient engagement is no longer optional—it’s essential for life sciences companies. In this article, ZS experts explore how global patient engagement strategies are evolving and identify three critical dimensions of consideration for effective patient engagement: https://bit.ly/3WCudYi

8

In an era of provider scarcity, ZS believes we have the opportunity to usher in healthcare abundance by using #AI and other technologies to fill in the gaps. ZS's Pratap Khedkar talked with the HLTH podcast to share our vision for the future of healthcare and the integration of AI. Listen now. https://bit.ly/3URKI2O

27